Table 1

Clinical and genetic data of carefully selected neuroblastoma samples that were included in this study
Sample number
 Lab number
 % Tumor cells
 Stage
 MYCN amp
 Ploidy
 Adrenal localization
 Age
 Dead/alive
 Overall survival (months)
 Type
NB1
 98T33
 95
 1
 No
 Tri
 Yes
 < 1 year
 Alive
 76.9
 Favorable
NB2
 99T84
 90
 1
 No
 Tri
 No
 < 1 year
 Alive
 71.8
 Favorable
NB3
 96T82
 90
 1
 No
 Tri
 Yes
 < 1 year
 Alive
 115.5
 Favorable
NB4
 99T129
 90
 1
 No
 Tri
 Yes
 < 1 year
 Alive
 71.7
 Favorable
NB5
 01T28
 90
 4
 Yes
 Di
 Yes
 > 1 year
 Dead
 5.6
 Unfavorable
NB6
 03T304
 100
 3*
 No
 Di
 Abdominal
 > 1 year
 Alive
 12.0
 Unfavorable
NB7
 03T236
 90
 4
 No
 ND
 Yes
 > 5 year
 Dead
 19.4
 Unfavorable
NB8
 00T54
 70
 1
 No
 Tri
 Yes
 < 1 year
 Alive
 62.6
 Favorable
NB9
 00T35
 >95
 4
 Yes
 Di
 Yes
 < 1 year
 Dead
 13.7
 Unfavorable
NB10
 99T125
 80
 3
 No
 Di
 Yes
 > 5 year
 Alive
 79.3
 Unfavorable
NB11 = NB4
 99T129
 90
 1
 No
 Tri
 Yes
 < 1 year
 Alive
 71.7
 Favorable
NB12
 02T192
 100
 4
 Yes
 Di
 Abdominal
 > 5 year
 Dead
 16.2
 Unfavorable
NB13
 D031
 >95
 4
 No
 Di
 Abdominal
 > 1 year
 Dead
 64.8
 Unfavorable
NB14
 E002
 >80
 4
 No
 ND
 Abdominal
 > 1 year
 Alive
 65.7
 Unfavorable
NB15
 E037
 >80
 4
 No
 ND
 Abdominal
 > 1 year
 Alive
 45.3
 Unfavorable
NB16
 E044
 >80
 4
 No
 ND
 Yes
 < 1 year
 Alive
 37.0
 Unfavorable
NB17
 E121
 >80
 4
 Yes
 ND
 Abdominal
 > 1 year
 Dead
 78.4
 Unfavorable
NB18
 04T121
 60
 3
 Yes
 Di
 Yes
 > 1 year
 Dead
 6
 Unfavorable

Samples were subdivided into favorable or unfavorable type based on MYCN amplification, ploidy and age at diagnosis. *Neuroblastoma or nodular gan-glioneuroblastoma. ND, not determined or unknown.

De Preter et al. Genome Biology 2007 8:401   doi:10.1186/gb-2007-8-1-401